Lasmiditan for acute treatment of migraine

被引：5
作者：
Parikh, S. [1 ]
机构：
[1] Thomas Jefferson Univ Hosp, Wayne, PA 19107 USA
来源：
DRUGS OF TODAY | 2021年 / 57卷 / 02期
关键词：
Lasmiditan succinate; 5-HT1F receptor agonists; Migraine treatment; Ditans; Treatment of pain; GENE-RELATED PEPTIDE; 5-HT1F RECEPTOR AGONISTS; GUINEA-PIG; TRIGEMINAL GANGLION; EPISODIC MIGRAINE; BINDING-SITES; EXPRESSION; BURDEN; DISCONTINUATION; COLOCALIZATION;
D O I：
10.1358/dot.2021.57.2.3238326
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Lasmiditan, a selective 5-HT1F receptor agonist, is a harbinger for the novel ditan class of medications for acute migraine treatment. Lasmiditan activates 5-HT1F receptors on presynaptic trigeminal nerve terminals, which impedes the release of calcitonin gene-related peptide (CGRP) from trigeminal nerve endings and thereby suppresses activation of the trigeminovascular system. Notably, lasmiditan does not result in vasoconstriction, making lasmiditan a migraine-specific acute treatment option for those with cardiovascular risk factors. However, lasmiditan does have centrally mediated side effects. This review will discuss the background of lasmiditan development, its preclinical pharmacology, safety, drug interactions and indications for use.
引用
收藏
页码：89 / 100
页数：12
相关论文
共 69 条
[1]   CLONING OF ANOTHER HUMAN SEROTONIN RECEPTOR (5-HT1F) - A 5TH 5-HT1 RECEPTOR SUBTYPE COUPLED TO THE INHIBITION OF ADENYLATE-CYCLASE [J].
ADHAM, N ;
KAO, HT ;
SCHECHTER, LE ;
BARD, J ;
OLSEN, M ;
URQUHART, D ;
DURKIN, M ;
HARTIG, PR ;
WEINSHANK, RL ;
BRANCHEK, TA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (02) :408-412
[2]   Migraine Burden of Disease: From the Patient's Experience to a Socio-Economic View [J].
Agosti, Reto .
HEADACHE, 2018, 58 :17-32
[3]   mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system [J].
Amrutkar, Dipak V. ;
Ploug, Kenneth B. ;
Hay-Schmidt, Anders ;
Porreca, Frank ;
Olesen, Jes ;
Jansen-Olesen, Inger .
PAIN, 2012, 153 (04) :830-838
[4]  
[Anonymous], REYV LASM
[5]   Molecular cloning and expression of the porcine trigeminal ganglion cDNA encoding a 5-ht1F receptor [J].
Bhalla, P ;
Sharma, HS ;
Wurch, T ;
Pauwels, PJ ;
Saxena, PR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 436 (1-2) :23-33
[6]   The acute treatment of episodic and chronic migraine in the USA [J].
Bigal, M. E. ;
Borucho, S. ;
Serrano, D. ;
Lipton, R. B. .
CEPHALALGIA, 2009, 29 (08) :891-897
[7]  
Blumenfeld Andrew M, 2020, J Fam Pract, V69, pS8
[8]  
Bouchelet I, 1996, MOL PHARMACOL, V50, P219
[9]   No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries:: similarity with human coronary artery [J].
Bouchelet, I ;
Case, B ;
Olivier, A ;
Hamel, E .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 (03) :501-508
[10]   Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study) [J].
Brandes, Jan Lewis ;
Klise, Suzanne ;
Krege, John H. ;
Case, Michael ;
Khanna, Rashna ;
Vasudeva, Raghavendra ;
Raskin, Joel ;
Pearlman, Eric M. ;
Kudrow, David .
CEPHALALGIA, 2019, 39 (11) :1343-1357
1234567